[go: up one dir, main page]

WO2012159075A1 - Compositions de sondes biologiques et leurs méthodes d'utilisation - Google Patents

Compositions de sondes biologiques et leurs méthodes d'utilisation Download PDF

Info

Publication number
WO2012159075A1
WO2012159075A1 PCT/US2012/038684 US2012038684W WO2012159075A1 WO 2012159075 A1 WO2012159075 A1 WO 2012159075A1 US 2012038684 W US2012038684 W US 2012038684W WO 2012159075 A1 WO2012159075 A1 WO 2012159075A1
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
binding
yeast
bioprobe
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/038684
Other languages
English (en)
Inventor
Sean A. GRAY
Kris Weigel
Gerard A. Cangelosi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seattle Biomedical Research Institute
Original Assignee
Seattle Biomedical Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Biomedical Research Institute filed Critical Seattle Biomedical Research Institute
Publication of WO2012159075A1 publication Critical patent/WO2012159075A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
    • G01N2333/39—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts

Definitions

  • Affinity reagents that bind to specific antigens of interest are critical tools in biomedical research, biomarker discovery, and diagnostic testing.
  • Generation of monoclonal antibodies (MAbs) by traditional methods, typically by the mouse hybridoma route, is a significant bottleneck in biomedical research and development.
  • MAbs in diagnostic tests often require significant optimization before being usable for diagnostic assays, and licensing costs can exceed all other test costs combined.
  • Cheaper and more available affinity reagents would greatly facilitate biomedical research and empower developers of new diagnostic tests.
  • scFv single-chain Fragment variable
  • Fab fragment antigen binding
  • yeast clones that bind specifically to antigens can be selected from naive libraries in 2-3 weeks. This selection process is much faster and less expensive than the mouse hybridoma route.
  • scFv selected by this method rarely perform well when secreted into solution.
  • yeast-displayed scFv are products of selection, in this case for activity in the environment of a yeast cell surface. Hence, many yeast-displayed scFv perform poorly in other environments, especially when secreted.
  • the present invention provides a bioprobe composition for selectively binding an antigen of interest in a sample.
  • the bioprobe composition comprises a lyophilized bioparticle displaying on its outer surface at least one heterologous antigen-binding molecule, wherein upon reconstitution of the bioparticle from the preserved state, the at least one heterologous antigen-binding molecule is capable of specifically binding the antigen of interest.
  • the bioparticle is selected from the group consisting of a cell, a cellular organelle, or a virus.
  • the cell is selected from the group consisting of a yeast, bacterium, plant, or animal cell.
  • the yeast is selected from the genera Saccharomyces or Pichia.
  • the bacterium is selected from the genera Escherichia or Bacillus.
  • the cellular organelle is a ribosome.
  • the virus is a bacteriophage.
  • the heterologous antigen-binding molecule is selected from the group consisting of an antibody-like molecule and a T cell receptor (TCR).
  • the antibody-like molecule comprises an antigen-binding fragment of an antibody or T cell receptor.
  • the antibody-like molecule is a single-chain antibody, a bispecific antibody, an Fab fragment, or an F(ab)2 fragment.
  • the single-chain antibody is a single-chain variable fragment (scFv), single-chain Fab fragment (scFab), V H H fragment, VNAR > or nanobody.
  • the lyophilized bioparticle is capable of being maintained between about 4 and 40 degrees Celsius before reconstitution of the bioparticle. In some embodiments, the lyophilized bioparticle is capable of being maintained for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, or 12 months, or more before reconstitution of the bioparticle.
  • the at least one heterologous antigen-binding molecule is displayed on the bioparticle surface prior to lyophilization by inducing expression and translocation of the molecule to, or assembly of the molecule on, the bioparticle surface.
  • the present invention provides a bioprobe composition for selectively binding an antigen of interest in a sample, comprising a lyophilized particle displaying on its outer surface at least one heterologous antigen-binding molecule, wherein upon reconstitution of the particle from the preserved state, the at least one heterologous antigen-binding molecule is capable of specifically binding the antigen of interest.
  • the present invention provides a method of detecting the presence of an antigen of interest in a biological sample.
  • the method comprises A) contacting a biological sample with a bioprobe composition described herein under conditions sufficient to permit the binding of the bioprobe with an antigen of interest; and B) detecting the binding of the bioprobe to the antigen of interest.
  • the method further comprises contacting the biological sample with a detection reagent that binds to the antigen of interest.
  • the detection reagent comprises a reagent selected from the group consisting of a polyclonal antibody, polyclonal antiserum, a monoclonal antibody, a TCR, a lectin, and a natural binding partner to the antigen.
  • the method further comprises contacting the biological sample with a detectably-labeled reporter reagent and separating the bioprobe from unbound reporter.
  • the binding of the antigen of interest to the bioprobe is detected using an antibody sandwich flow cytometric assay, cell bioprobe immunofluorescence microscopy, or an ELISA-like assay. In some embodiments, the binding of the antigen of interest present in the biological sample to the bioprobe is detected by using a competitive inhibition assay.
  • the biological sample is selected from the group consisting of blood, urine, sputum, mucus, saliva, cerebral spinal fluid, tissues, stool, nutrient sources, or processed derivatives thereof.
  • the present invention provides a method of detecting the presence of an antigen of interest in a biological sample.
  • the method comprises A) contacting a biological sample with a capture reagent that binds to the antigen of interest; and B) contacting the biological sample with a detection reagent under conditions sufficient to permit the binding of the detection reagent with an antigen of interest, wherein the detection reagent comprises a bioprobe composition described herein.
  • the detection reagent further comprises a detectable label.
  • the method further comprises contacting the biological sample with a detectably-labeled reporter agent that specifically binds to the bioprobe composition, and separating the capture reagent from unbound reporter agent.
  • the present invention provides a method for validating a candidate biomarker as a biomarker of a biological state.
  • the method comprises A) contacting a library comprising a plurality of bioparticles displaying heterologous antigen-binding molecules with a detectably-labeled candidate biomarker of a biological state under conditions sufficient to permit the binding of a displayed heterologous antigen-binding molecule with the labeled candidate biomarker; B) isolating the bioparticles displaying heterologous antigen-binding molecules bound to the candidate biomarker; C) propagating the bioparticles isolated in step (B); D) inducing expression and surface display of the heterologous antigen-binding molecules in the bioparticles propagated in step (C); E) preserving the bioparticles displaying the heterologous antigen-binding molecules induced in step (D); and F) validating the candidate biomarker as a biomarker for the biological state by contacting biological samples obtained from a plurality of individuals exhibiting and
  • the present invention provides a kit for selectively binding an antigen of interest in a sample.
  • the kit comprises A) the bioprobe composition in any one of Claims 1-15; and B) reconstitution buffer.
  • the kit further comprises detection reagent, detectably-labeled reporter reagent, instructions for use, and/or at least one detectably-labeled antigen of interest as a control. DESCRIPTION OF THE DRAWINGS
  • FIGURE 1 graphically illustrates the pre- and post-lyophilization antigen binding and specificity of yeast-scFv bioprobe clone 350-E2.
  • Fresh, non-lyophilized 350-E2 yeast and lyophilized, rehydrated 350-E2 yeast were split into 10 aliquots.
  • each aliquot received either no antigen, or 100 nM each of antigens 350, 142, Jacob, or 780.
  • Biotinylated antigens were used in every case, and antigen binding was detected by incubating with SA-PE.
  • Assays illustrated in Panel B were performed as in Panel A, except that non-biotinylated antigens were used and antigen binding was detected by incubation with rabbit-anti-350 antiserum followed by goat-anti-rabbit-phycoerythrin (GaR-PE).
  • the percent of PE-positive yeast was determined by gating the PE fluorescence relative to the "no antigen" control. Values are means of three experiments plus or minus the standard deviation. The clear bars indicate binding of the fresh yeast to each antigen, and the bars with diagonal lines indicate binding of the lyophilized/reconstituted yeast to the antigens.
  • FIGURE 2 graphically illustrates the lower limit of detection of 350 antigen by lyophilized/reconstituted yeast-scFv bioprobe clone 350-E2.
  • Lyophilized 350-E2 yeast cells were reconstituted in 1 mL YWB and split into 1 1 equal aliquots. Each aliquot was incubated with 10 concentrations of 350-biotin antigen ranging from 20 nM to 0.04 nM (plus the 0 nM control) in twofold serial dilutions in 2.5 mL (total volume) YWB. Bound 350 antigen was detected by incubating with a rabbit anti-350 antiserum followed by GaR-PE detection. Samples were analyzed by flow cytometry.
  • FIGURE 3 illustrates the immunofluorescence assay using lyophilized/reconstituted yeast-scFv bioprobe reagents.
  • Panel A is a photomicrograph showing the lyophilized/reconstituted 350-E2 yeast bioprobe binding to cognate 350 antigen at 500 nM concentration. Bound antigen was detected by incubating with a rabbit anti-350 antiserum followed by GaR-FITC detection and photographed at 90 x magnification and digitally zoomed 3x to visualize staining patterns.
  • Panel B graphically illustrates results of an experiment in which 350-biotin was tested in triplicate using 1 1 concentrations ranging from 160 nM down to 0.14 nM in twofold serial dilutions. For each concentration, three fields were photographed twice, first in visible mode, and then in FITC mode. The percent of FITC-positive yeast were calculated and graphed relative to the concentration of 350 antigen.
  • FIGURE 4 graphically illustrates the ELISA-like assay using lyophilized/reconstituted yeast-scFv bioprobe reagents.
  • Binding of cognate 350 antigen to lyophilized/reconstituted 350-E2 yeast bioprobes was tested in triplicate in eight concentrations from 100 nM to 0.78125 nM, in addition to no antigen control and to 100 nM each of non-cognate antigens 142, 780, and Jacob.
  • the binding was detected by staining with rabbit anti-350 polyclonal antiserum followed by GaR conjugated to horseradish peroxidase (GaR-HRP), and ascertaining the absorbance spectrophotometrically at 450 nm.
  • GaR-HRP horseradish peroxidase
  • FIGURE 5 graphically illustrates results of a lyophilization time course assay using yeast-scFv bioprobe clone 780-23.
  • One aliquot of lyophilized yeast was removed at intervals over the course of 86 days and stained first for c-myc-FITC expression followed by staining with cognate 780-biotin or three non-cognate antigens (Jacob-biotin, 350-biotin, or 142-biotin, plus a no antigen control).
  • the percent of PE-positive yeast were determined using the no-antigen stain as a gating reference.
  • the graph depicts the percent positive yeast (y-axis) at each of the time points tested (x-axis) for each of the four antigens.
  • the assay was terminated when binding to cognate 780-biotin antigen had dropped below 15%.
  • FIGURE 6 graphically illustrates results of a lyophilization time course assay using yeast-scFv bioprobe clone 350-12.
  • Three individual colonies of clone 350-12 were lyophilized separately on different days. Every 3 to 5 days, one aliquot of each was tested for binding to cognate antigen (100 nM 350-biotin) and to a non-cognate control antigen (100 nM 780-biotin) as described for FIGURE 5.
  • the graph depicts the binding to the cognate or non-cognate antigens, as determined by percent of PE-positive yeast in flow cytometric analysis (y-axis), for each of the time periods tested (x-axis). Because of the staggered lyophilization dates, data were grouped into groups of 2 to 3 days, and each point represents the average and standard deviation for the day range indicated in the graph.
  • yeast-displayed scFv yeast-displayed scFv directly as detection reagents.
  • yeast cell provides a surface on which to present the scFv, which is similar in nature to a plastic or ceramic bead particle that has been coupled to an antibody.
  • YDIP Yeast Display Immunoprecipitation
  • CIFC competitive-inhibition flow cytometry
  • YDIP yeast-scFv probes must be cultured and induced to express scFv before each assay.
  • YDIP requires mass spectrometry to detect captured antigens, a potentially cumbersome procedure requiring significant laboratory instrumentation.
  • CIFC also has its own limitations, being an indirect format that is susceptible to false-positive results due to non-specific inhibition of fluorescent antigen binding.
  • bioprobes were generated incorporating whole yeast cells displaying scFv on their surfaces (yeast-scFv bioprobes).
  • yeast-scFv bioprobes were used in place of soluble purified scFv or traditional monoclonal antibodies.
  • a nonimmune library of human scFv displayed on the surfaces of yeast cells was screened for clones that bind to recombinant cyst proteins of Entamoeba histolytica, an enteric pathogen of humans.
  • yeast-scFv clones could be stabilized by lyophilization without loss of the structural and receptor integrity.
  • the lyophilized yeast-scFv bioprobes were capable of later use in detection assay formats in which the yeast-scFv served as substitutes for solid support-bound monoclonal antibodies. Specific binding of antigen by the reconstituted yeast-scFv bioprobes was detected by staining with rabbit polyclonal antibodies.
  • lyophilized yeast-scFv reagents retained full binding activity and specificity for their cognate antigens after 4 weeks of storage at room temperature in the absence of desiccants or stabilizers.
  • yeast-scFv bioprobes demonstrate that the bioprobes of the present invention are sufficiently stable to maintain structural and functional integrity during the lyophilization/storage/reconstitution process. Additionally, the complex nature of the cell surface and cytoplasm do not interfere in reporter and/or detection reagents, such as polyclonal antibodies and horseradish peroxidase. Moreover, the antigen-specific bioprobe reagents (e.g., yeast-scFv bioprobes) provide the additional advantage of being easily selected from nonimmune libraries in 2-3 weeks, produced in vast quantities, and packaged in lyophilized form for extended shelf life before utilization in various assay applications.
  • reporter and/or detection reagents such as polyclonal antibodies and horseradish peroxidase.
  • antigen-specific bioprobe reagents e.g., yeast-scFv bioprobes
  • the present invention provides a bioprobe composition for selectively binding an antigen of interest in a sample.
  • the bioprobe composition comprises a lyophilized bioparticle displaying on its outer surface at least one heterologous antigen-binding molecule, wherein upon reconstitution of the bioparticle from the preserved state, the at least one heterologous antigen-binding molecule is capable of specifically binding the antigen of interest.
  • bioparticle is used to refer to any particle derived from a biological system while retaining the integrity of heterologous antigen-binding molecules displayed on the surface of the bioparticle.
  • bioparticle can encompass intact cells, cellular organelles, viruses, or other biological constructs that can be assembled, propagated, or generated to display on the outer surface at least one heterologous antigen-binding molecule.
  • the bioparticle there is no requirement that the bioparticle be living or demonstrate metabolic integrity post-lyophilization. However, the bioparticle must be amenable to lyophilization and subsequent reconstitution.
  • the term "functional" is used to indicate that the displayed heterologous antigen-binding molecule(s) retain the capacity to selectively bind the antigen of interest.
  • the bioparticle is a cell.
  • the bioparticle can be any cell that can be made to express and/or display a heterologous antigen-binding molecule on its surface and that can retain its structural integrity upon lyophilization and subsequent reconstitution.
  • a determination of the cell's integrity after reconstitution can be made with any number of simple assays. Such assays can include simple observation using microscopy or flow cytometry in combination with the binding of labeled antigen, as described herein (see e.g., Example 5).
  • the cell is a microbial cell, such as a yeast or bacterial cell.
  • the cell is a plant or animal cell.
  • the cells that contain rigid cell walls are selected for use as bioparticles because the rigid cell wall can enhance the retention of integrity after the lyophilization and subsequent reconstitution processes.
  • the bioparticle cell is a yeast cell.
  • yeasts include yeast selected from the genera Saccharomyces or Pichia, for example, Saccharomyces cerivisiae or Pichia searchis.
  • yeast bioprobes were generated by screening libraries of Saccharomyces cerivisiae displaying human-derived single-chain variable antibody fragments (scFv) on their surface.
  • scFv single-chain variable antibody fragments
  • persons of skill in the art will recognize that the present compositions are not limited to such embodiments, but rather encompass any yeast amenable to display of heterologous antigen-binding molecule on its surface using common recombinant DNA techniques. See, e.g., Sambrook, et al. (2000) or Ausubel, et al. (1999).
  • the bioparticle cell is a bacterium.
  • the bacterium can be Gram positive or Gram negative.
  • Exemplary bacteria are selected from the genera Bacillus (Gram positive) and Escherichia (Gram negative). Specific examples include Bacillus megaterium and Escherichia coli.
  • Transgenic bacteria have been used to display library of heterologous polypeptides, including scFv antibodies, which are retained on the surface for subsequent cell sorting. See, e.g., Georgiou, G., et al, "Display of Heterologous Proteins on the Surface of Microorganisms: From the Screening of Combinatorial Libraries to Live Recombinant Vaccines," Nat. Biotechnol. 75:29-34, 1997.
  • the present compositions are not limited to such embodiments, but rather encompass any bacterium amenable to display of heterologous antigen-binding molecule on its surface using common recombinant DNA techniques. See, e.g., Sambrook, et al. (2000) or Ausubel, et al. (1999).
  • the bioparticle is a non-microbial cell, such as an animal cell or a plant cell.
  • scFvs have been displayed and isolated from human embryonic kidney 293T (HEK-293T) cells (see, e.g., Ho, M. et al, "Isolation of Anti-CD22 Fv With High Affinity by Fv Display on Human Cells," Proc. Natl. Acad. Sci. USA 703:9637-9642, 2006.
  • the bioparticle is a cellular organelle.
  • An exemplary organelle is the ribosome, which has been previously used to display large repertoires of antibodies and antibody-like molecules. See, e.g., He, M. and Khan, F., "Ribosome Display: Next-Generation Display Technologies of Antibodies In Vitro," Expert Rev. Proteomics 2:421-430, 2005.
  • the bioparticle is a virus.
  • An illustrative example is a bacteriophage.
  • Use of bacteriophages to display libraries of exogenous polypeptides has been established. For example, using filamentous M13-derived bacteriophages, many display libraries have been made by expressing the exogenous polypeptides as fusions with the bacteriophage coat protein pill. As the virus is assembled within the host bacterium, the fusion protein is transported to the bacterial periplasm and incorporated into the phage particle. Additional Ml 3 filamentous proteins that have been utilized for fusion with the exogenous polypeptides include pVI, pVII, pVIII, and pIX. In the context of antibody-like polypeptides, the result is a library of diverse antibody-like polypeptides with intact binding properties linked to the DNA that encodes them, which enables the subsequent selection and propagation of polypeptides exhibiting particular binding properties.
  • heterologous antigen-binding molecule is used to refer to any molecule that binds to an antigen.
  • heterologous specifically refers to the characteristic that the antigen-binding molecule is not naturally occurring in or on the bioparticle, but rather is caused to be expressed and/or displayed on the bioparticle by experimental manipulation.
  • the heterologous antigen-binding molecule selectively binds to its cognate antigen (e.g., the antigen of interest) as compared to a non-cognate antigen.
  • the term "selectively binds" is used to refer to the enhanced affinity and avidity binding characteristics of the heterologous antigen-binding molecule for the cognate antigen as compared to the non-cognate antigen.
  • the heterologous antigen-binding molecule can bind to its cognate antigen with 5%, 10%, 25%, 50%, 75% or greater efficiency as compared to any non- cognate antigen.
  • the heterologous antigen-binding molecule can bind to its cognate antigen with an efficiency that is more than 2, 5, 10, 20 times or more as compared to binding to its non-cognate antigen.
  • the heterologous antigen-binding molecule is an antibody- like molecule.
  • antibody-like molecule encompasses antibodies or fragments thereof, derived from any antibody -producing animal (e.g., fish, reptiles, birds, and mammals, including mice, rats, rabbits, camelids, and primates, including human).
  • exemplary antibody-like molecule can include antibodies such as monoclonal, multispecific antibodies (e.g., bispecific antibodies), chimeric antibodies, anti-idiotype antibodies, and may be any intact molecule or fragment thereof, and of any isotype.
  • antibody fragment refers to a portion derived from or related to a full-length antibody, generally including the antigen-binding or variable region thereof.
  • Illustrative examples of antibody fragments include Fab, Fab', F(ab)2, F(ab3 ⁇ 4 and Fv fragments, scFv fragments, diabodies, linear antibodies, single-chain antibody molecules and multispecific antibodies formed from antibody fragments.
  • single-chain antibody refers to an antibody fragment that contains at least one antigen-binding region in a single polypeptide molecule.
  • single-chain Fv or “scFv” specifically refers to an antibody fragment that comprises the Vfj and VL domains of an antibody, wherein these domains are present in a single polypeptide chain.
  • the Fv polypeptide further comprises a polypeptide linker between the Vfj and VL domains, which enables the scFv to form the desired structure for antigen binding.
  • An scFv can also be generated to be multivalent, namely to contain multiple pairings of VJJ and VL domains in a single polypeptide chain, where each pairing can bind to the same or different antigen.
  • single-chain antibodies include single-chain Fab fragments (scFab) and nanobodies.
  • scFab single-chain Fab fragments
  • Fab single fragment antigen-binding region
  • nanobodies can include VfjH fragments, which refers to fragments of heavy chain antibodies from camelids, and Vj ⁇ AR fragments, which refers to fragments of heavy -chain antibodies derived from cartilaginous fish.
  • the heterologous antigen-binding molecule is a T-cell receptor.
  • T-cell receptors are members of the immunoglobulin superfamily of proteins and function to recognize and/or bind to antigens.
  • TCRs recognize antigens presented on the MHC.
  • Native TCRs exist in ⁇ and ⁇ dimeric forms, which are structurally similar. When dimerized, the ⁇ and ⁇ forms appear very similar to an Fab fragment of a typical antibody.
  • the heterologous antigen-binding molecule comprises antigen-binding portions of a TCR.
  • the antigen-binding portions of a TCR include engineered single-chain TCRs and TCR fragments comprising the variable regions of ⁇ , ⁇ , ⁇ and ⁇ chains, alone or paired in various combinations. Display of TCRs in single-chain and dimeric form on ribosomes, bacteriophage, cell, or proteinaceous particle is described in International Publication No. WO 2004/044004.
  • the bioparticles of the present invention display at least one heterologous antigen-binding molecule on their surface.
  • display refers to the position of the antigen-binding molecules in the environment immediately beyond the outer surface of the bioparticle.
  • the antigen-binding domains of the molecules are in communication with the surrounding environment and are thus capable of coming into physical contact with and binding their cognate antigens.
  • the antigen-binding molecules remain anchored or connected to the bioparticle.
  • the heterologous antigen-binding protein is a fusion with a domain of a protein that is endogenous to the bioparticle and that spans the outer surface (e.g., plasma membrane, cell wall, capsid, and the like) of the bioparticle.
  • a domain of a protein that is endogenous to the bioparticle and that spans the outer surface (e.g., plasma membrane, cell wall, capsid, and the like) of the bioparticle.
  • domains are known in the art for various bioparticles.
  • the display of exogenous proteins on Ml 3 filamentous bacteriophages can utilize fusions with coat proteins pill, pVI, pVII, pVIII, and pIX.
  • libraries of yeast cells displaying human scFv utilized Agal-Aga2 to tether the human scFv to the yeast cell walls.
  • the inventors generated bioprobes comprising bioparticles with the surprising property of being capable of lyophilization and subsequent reconstitution, wherein the reconstituted bioparticles retained the display of functional antigen-binding molecules for specific binding to the antigen of interest.
  • Lyophilization can be performed according to any of various well-known lyophilization protocols. In some embodiments, the lyophilization protocol simply involves flash freezing of the bioprobes, followed by drying in a suitable lyophilization apparatus. In additional embodiments, a lyophilization reagent can be used in which the bioprobes are first immersed and/or suspended.
  • Suitable lyophilization reagents include, but are not limited to, phosphate-buffered saline or specialized reagents such as 2X Concentrate Lyophilization Reagent (OPS Diagnostic, LLC).
  • a freeze-drying indicator reagent may also be used, such as, for example, the Freeze Drying Indicator from OPS Diagnostic, which includes a colorimetric reagent that turns from red in the unlyophilized state to blue in the lyophilized state.
  • yeast bioprobes displaying human scFv were lyophilized by concentrating the yeast bioprobes by centrifugation, flash-freezing the concentrated yeast in liquid nitrogen for approximately 15 seconds, followed by application of a vacuum overnight in a Millrock Technology Model BT48A lyophilizer.
  • the lyophilization process permits the prolonged storage of the bioprobes in a preserved state that does not require refrigeration or other cumbersome storage conditions. Accordingly, the present invention provides bioprobe compositions wherein the lyophilized bioparticle is capable of being maintained in the preserved state for a prolonged period of time, such as 1, 2, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 365 days, or more, or any time period therein. Stated otherwise, the lyophilized bioparticle is capable of being maintained in the preserved state for at least about 1 month to a year or more, including any time within that range.
  • a prolonged period of time such as 1, 2, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 365 days, or more, or any time period therein. Stated otherwise, the lyophilized bioparticle is capable of being maintained in the preserved state for at least about 1 month to a year or more, including any
  • the term “maintained” is used to refer to the preservation or retention of the physical characteristics of the bioparticle while in the preserved state, including the structural integrity of the bioparticle and retention of the functional heterologous antigen- binding molecule(s) displayed on the outer surface.
  • the present invention also provides bioprobe compositions wherein the lyophilized bioparticle is capable of being maintained in the preserved state under a wide range of storage temperatures ranging between below freezing and above 50° Celsius, such as between about 4°C and about 40 C, or any range therein.
  • the lyophilized bioparticle is maintained within about 10°C of room temperature, which is typically considered to be between 20°C and 25°C. More preferably, the lyophilized bioparticle is maintained within about 9°C, 8°C, 7°C, 6°C, 5°C, 4°C, and 3°C of room temperature.
  • reconstitution refers to the conversion of the bioparticle from a preserved state to an active state wherein the bioparticle is capable of interacting with components of a biological sample and specifically binding to its cognate antigen.
  • reconstitution of the bioparticle involves contacting the lyophilized bioparticle with an appropriate buffer according to protocols known in the art.
  • buffers useful for reconstitution comprise PBS and/or BSA.
  • the reconstitution buffer for a small aliquot of lyophilized yeast bioprobes is 100 JL of PBS + 0.5% BSA (PBSB).
  • the reconstitution can be accomplished primarily by rehydration effected by the biological sample itself, if the biological sample contains sufficient liquid.
  • the buffer contains additional components, such as protease inhibitors, to assist preservation of the antigen of interest and the heterologous antigen-binding molecule.
  • antigen of interest refers to any antigen that serves as a cognate antigen to the heterologous antigen-binding molecule. It will be apparent to persons of ordinary skill in the art that there is no limitation on the character, type, or source of antigen in the practice of the present invention.
  • embodiments of antigens can include toxins, biomarkers for microbial or parasitic infection, biomarkers for the presence of transformed cells, such as cancer cells, biomarkers for a biological state, such as a disease state, and endogenous biomarkers indicating a particular genotype or phenotype.
  • Antigens can be peptides, polypeptides, and non-protein antigens. In some embodiments, the antigens are non-protein small molecule compounds, such as drugs, metabolites, environmental pollutants, and the like.
  • bioprobe compositions of the present invention provide several advantages over the affinity reagents currently available.
  • lyophilized yeast-scFv provide several advantages over the affinity reagents currently available.
  • the heterologous antigen-binding protein displayed on the surface of the lyophilized bioparticles there is no need for further induction or assembly cycles after reconstitution. No additional culture or growth media (and related equipment) is required, adding to the efficiency and cost savings.
  • the generation of bioprobes of the present invention permits production of large quantities (e.g., hundreds to thousands) of aliquots in a short time period at a cost of cents per aliquot.
  • bioprobes of the present invention permits easy and long-term storage of the bioprobes of the present invention. Therefore, shipping and storage do not require expensive maintenance of low temperatures or use of additional chemicals.
  • bioprobes are amenable for use as affinity reagents in locations that lack growing or storage facilities in simple, yet sensitive assays that do not require sophisticated equipment.
  • the present invention provides a bioprobe composition for selectively binding an antigen of interest in a sample, which comprises a lyophilized particle displaying on its outer surface at least one heterologous antigen-binding molecule, wherein upon reconstitution of the bioparticle from the preserved state, the at least one heterologous antigen-binding molecule is capable of specifically binding the antigen of interest.
  • the term "particle” refers to the same elements as a bio-particle. However, in addition to any particle derived from a biological system, the term particle also refers to particles that are not derived from a biological system, but rather are commonly used in the art to interact with biological systems. Such particles include inorganic microspheres, microparticles, nanoparticles, beads, and the like, to which antigen-binding molecules can be attached.
  • the antigen-binding molecules can include the same embodiments described above. However, instead of utilizing the expression of fusion protein incorporating trans-surface anchoring domains, embodiments provided by this aspect are attached according to routine protocols known in the art.
  • Illustrative examples include, but are not limited to, homo- and hetero-bifunctional crosslinking chemistries (e.g. carbodiimide, N-hydroxysuccinimide ester, maleimide, etc.), and biotin/streptavidin coupling.
  • homo- and hetero-bifunctional crosslinking chemistries e.g. carbodiimide, N-hydroxysuccinimide ester, maleimide, etc.
  • biotin/streptavidin coupling e.g. carbodiimide, N-hydroxysuccinimide ester, maleimide, etc.
  • the described bioprobe compositions can be employed in methods for detecting and/or selectively binding an antigen of interest in a sample.
  • the bioprobe compositions can be used as a capture reagent that selectively binds to the antigen of interest (i.e., molecules comprising the cognate antigen for the displayed heterologous antigen-binding protein) and does not bind the other non- cognate antigens present in the sample.
  • the antigen of interest i.e., molecules comprising the cognate antigen for the displayed heterologous antigen-binding protein
  • any antigen of interest that is bound to the bioprobe can be selectively removed from the other components of the sample. Detection of binding can be accomplished according to various assay formats known in the art. Illustrative examples are described below.
  • the method comprises contacting a sample with a bioprobe composition as described herein under conditions sufficient to permit the binding of the bioprobe (via the heterologous antigen-binding protein) to the antigen of interest, and detecting the binding of the bioprobe to the antigen of interest.
  • the method further comprises contacting the sample with a detection reagent that also binds to the antigen of interest. While it is preferred that the detection reagent specifically binds to the antigen of interest, it is not critical that it demonstrates a high degree of specificity because the specificity is provided in the assay by the bioprobe composition. However, it will be apparent that the detection reagent should not compete with the binding of the bioprobe composition to the antigen of interest.
  • the detection reagent include polyclonal antibodies (e.g., as included in a polyclonal antiserum), monoclonal antibodies, TCRs, lectin, and any known natural binding partner to the antigen.
  • the detection reagent is detectably labeled.
  • Detectable labels can include, but are not limited to, functional enzymes, chemiluminescent molecules, fluorescent molecules, phosphorescent molecules, radioactive labels, spin labels, redox labels, and the like, specific examples of which are well known in the art.
  • the sample is also contacted with a reporter reagent.
  • the reporter reagent performs as a secondary detection reagent, wherein the reporter reagent binds to a component common to the (primary) detection reagents.
  • a goat anti-rabbit antibody was used to bind to and detect the polyclonal rabbit antibodies (in serum), which was bound to the antigen of interest, which in turn was bound to the yeast bioprobes.
  • the detection reagent is not detectably labeled, whereas the reporter reagent that binds to the detection agent is detectably labeled.
  • the method contains a step wherein the bioprobe/antigen/detection reagent complex is separated from any unbound detectable label.
  • the complex is typically immobilized on a solid substrate, such as the bottom of a well.
  • the unbound reagent with a detectable label is removed by one or more rinse procedures.
  • no immobilization is required by virtue of the size of the bioprobe, which facilitates the separation of the labeled bioprobe/antigen complex from unbound detectably-labeled reagent and/or unbound antigen.
  • the bioprobe can be immobilized to solid surfaces such as a microwell plates. Simple wash protocols can be used.
  • centrifugation can be employed to generate pellets followed by resuspension in a wash buffer. This can be performed once or in a series to selectively isolate the labeled bioprobe/antigen complex from unbound detectably label reagent and/or unbound antigen.
  • the labeled bioprobe/antigen complex is separated from unbound detection reagent, followed by detection and/or quantification by use of various assays known in the art. As described below, such as in Examples 3 and 5, an antibody sandwich flow cytometric assay (ASFC) is used to quantify antigen binding by the bioprobe.
  • ASFC antibody sandwich flow cytometric assay
  • the labeled bioprobe/antigen complex is detected and/or quantified by use of an ELISA-like enzymatic assay, which does not necessarily require immobilization of the antigen/capture reagent complex.
  • the labeled bioprobe/antigen complex is quantified by use of a detection reagent bound to an enzyme with detectable activity, such as horseradish peroxidase (HRP).
  • HRP horseradish peroxidase
  • the activity of the enzyme is quantified by virtue of a characteristic of the product of enzyme activity, such as a color change, or light absorbance at a specific wavelength.
  • a characteristic of the product of enzyme activity such as a color change, or light absorbance at a specific wavelength.
  • HRP a representative ELISA- like assay using HRP is described in more detail in Example 8.
  • an immunofluorescence microscopy assay is used to detect and quantify the presence of labeled bioprobe/antigen complex, such as described in more detail in Example 7.
  • binding of the bioprobe to the antigen complex is detected and quantified without the use of a labeled reporter, but rather is detected and quantified using a competitive inhibition assay.
  • the assay comprises further contacting the sample with a detectably-labeled antigen of interest, wherein binding of the bioprobe to any unlabeled antigen of interest from the sample blocks binding of the bioprobe to the detectably-labeled antigen of interest.
  • binding of the antigen of interest results in a detectable reduction of labeled antigen of interest bound to the bioprobe compared to a control sample not containing any antigen of interest. See, e.g., Gray, S.A., et al, Biotechnol Bioeng 705:973-981 (2010).
  • bioprobe serving as a capture reagent.
  • the invention is not limited to this aspect.
  • capture reagents can be used that incorporate antigen-specific binding molecules.
  • Non-limiting examples include magnetic beads conjugated to polyclonal antibodies (antiserum), immobilized antibodies, antibody-like molecules, or fragments thereof, lectins, TCRs, or any naturally occurring binding partner.
  • the bioprobe compositions of the present invention can thus be used as a detection reagent. Detection/quantification of binding of the bioprobe composition to the captured antibody can be performed by incorporating any well-known detectable label, or by use of a detectably-labeled secondary detection reagent specific for a component of the bioprobe composition.
  • the sample is a biological sample.
  • biological samples include blood, urine, sputum, mucus, saliva, cerebral spinal fluid, tissues, stool, or processed derivatives thereof. Use of such samples can facilitate the use of the methods of the present invention for purposes of detecting particular biological states, the presence of pathogens, parasites, or to determine particular phenotypes, depending on the antigen of interest.
  • the sample is an environmental sample, such as a water sample.
  • the sample is from a nutrient source, such as from the food or potable water supply, for example, milk, juice, meat, crop samples, animal feed, and the like, or any processed derivatives thereof. The methods of the present invention can be applied to the monitoring of these samples to monitor for toxins and contaminants, or, for example, in efforts to monitor against agents used in acts of bioterrorism.
  • Biomarker discovery is the search for novel molecular indicators of biological state. For example, proteomic analysis using tandem mass spectrometry can be used to identify proteins that are found in the sera of people with a specific disease, but not in the sera of healthy people. In this process, analysis of a small set of diseased and healthy samples can identify scores or hundreds of candidate markers. These must be validated by analysis of much larger sample sets. As described herein, validation steps typically begin with the generation of antibodies in animals immunized with recombinant candidate biomarkers as antigens. The antibodies are then used in formats such as dot blot or ELISA to test large sample sets for antigen occurrence. Raising antibodies in animals is costly and requires months to complete.
  • the present invention streamlines this step by providing for very rapid generation of specific binding reagents. In so doing, it also makes it possible to screen larger numbers of candidate markers, thereby increasing the probability of a successful biomarker search.
  • the present invention provides a method for validating a candidate biomarker as a biomarker for a biological state.
  • the method comprises contacting a library comprising a plurality of bioparticles displaying heterologous antigen-binding molecules with a detectably-labeled candidate biomarker of a biological state under conditions sufficient to permit the binding of a displayed heterologous antigen-binding molecule with the labeled candidate biomarker.
  • each bioparticle in the library displays a clonal population of the same antigen-binding molecule.
  • each bioparticle specifically binds to a single cognate antigen, although the antigen-binding molecules preferably vary from bioparticle to bioparticle such that the library can be used for a wide variety of candidate antigens/biomarkers.
  • the bioparticles displaying heterologous antigen-binding molecules bound to the candidate biomarker are detected, isolated, and propagated.
  • the now clonal (or near clonal) population of bioparticles can be induced to express and/or display the heterologous antigen-binding molecule on its surface.
  • the bioparticles displaying the heterologous antigen-binding molecule are then preserved, preferably by lyophilization.
  • the preserved bioparticles can be stored or distributed for use in validation studies from a plurality of sources to statistically ascertain whether the candidate biomarker is associated with the biological state.
  • bioparticle embodiments of this aspect must be capable of propagation.
  • Illustrative examples are cells and viruses.
  • the bioparticles once the bioparticles are isolated, propagated, and induced to display the heterologous antigen-binding molecule, they can be preserved without regard to their viability after reconstitution. As explained above, the necessary feature is that the preserved bioparticles must retain structural integrity, including the display of functional heterologous antigen-binding molecules.
  • biomarkers such as the presence or absence of disease, pathogen, macroparasite, or toxin, the stage of disease or infection, the receptivity to particular treatments, or susceptibility/sensitivity to a disease, and the like.
  • a library useful in the practice of this method is a yeast library displaying human-derived scFv, as described below (see, e.g., Examples 2 and 3).
  • Other well-known examples include E. coli, bacteriophage, and ribosome display libraries, as described herein.
  • the present invention provides a kit for selectively binding an antigen of interest in a sample to permit the use of the compositions and methods described above.
  • the kit comprises the bioprobe compositions as described above and a reconstitution buffer.
  • the kit can be modified to also include detection reagents that specifically bind to the same antigen of interest as the bioprobe composition, albeit non-competitively.
  • the detection reagent can contain a detectable label.
  • the kit can also include a reporter reagent that serves as a secondary detection reagent.
  • the kit contains detectably-labeled antigen of interest for use as control.
  • the kit contains printed instructions for use.
  • the kit of the present invention comprises at least one aliquot of the bioprobe in a tube-like device.
  • the tube-like device is separated into at least two chambers by a filter or permeable membrane.
  • One chamber contains the lyophilized bioprobe, whereas a second chamber contains reconstitution buffer.
  • the reconstitution buffer can optionally comprise additional reagents, such as protease inhibitors.
  • the reconstitution buffer is mixed or contacted with the sample (such as feces from a fecal swab).
  • the buffer and sample are mixed and allowed to contact the lyophilized bioprobe. This can be performed by centrifugation, which in this embodiment would permit the flow of antigen and reconstitution buffer to the chamber with the bioprobe composition, but would prevent the flow of macro particulates.
  • yeast-scFv bioprobe assay formats Induced yeast-scFv bioprobes were lyophilized to yield stable reagents that did not require cultivation or special storage conditions, and were immediately usable following rehydration.
  • simple direct assay formats were developed that used yeast-scFv reagents in combination with basic laboratory resources.
  • yeast-scFv probes were isolated that bound specifically to putative cyst proteins of the parasite Entamoeba histolytica, the causative agent of intestinal amoebiasis in developing countries (Haque, R., et al, "Epidemiologic and Clinical Characteristics of Acute Diarrhea With Emphasis on Entamoeba histolytica Infections in Preschool Children in an Urban Slum of Dhaka, Bangladesh," Am J Trop Med Hyg 69:398 ⁇ 105, 2003; Petri, W.A., Jr., et al, "Estimating the Impact of Amebiasis on Health," Parasitol Today 76:320-321, 2000).
  • E. histolytica proteins were selected for this study on the basis of their elevated mRNA expression in the cyst stage relative to the trophozoite stage of the parasite (Ehrenkaufer, G.M., et al, "Identification of Developmentally Regulated Genes in Entamoeba histolytica: Insights Into Mechanisms of Stage Conversion in a Protozoan Parasite," Cell Microbiol 9: 1426-1444, 2007). Fragments of each protein were selected and cloned to minimize sequence overlap with homologs from the commensal species E. dispar and E. moshkovskii. These species are closely related to E.
  • Jacob proteins appear on the surface of encysting parasite and are abundant in the walls of mature cysts (Chatterjee, A., et al, "Evidence For a "Wattle and Daub” Model of the Cyst Wall of Entamoeba," PLoS Pathog 5:el000498, 2009; Ghosh, S.K., et al, "The Jacob2 Lectin of the Entamoeba histolytica Cyst Wall Binds Chitin and Is Polymorphic," PLoS Negl Trop Dis 4:e750, 2010).
  • chromodomain-containing proteins (EHI 142000, EHI l 15350 and EHI 000780; hereafter termed 142, 350, and 780, respectively) were also selected because chromodomain proteins fulfill stage-specific functions in other systems (Perez-Toledo, K., et al, "Plasmodium falciparum Heterochromatin Protein 1 Binds to Tri-Methylated Histone 3 Lysine 9 and Is Linked to Mutually Exclusive Expression of Var Genes," Nucleic Acids Res 37:2596-2606, 2009; Smith, T.J., et al, "Sequence Variation Within Botulinum Neurotoxin Serotypes Impacts Antibody Binding and Neutralization,” Infect Immun 73:5450-5457, 2005). Additionally, 780 was detected in 2 out of 5 E. histolytica cyst samples that were subjected to shotgun proteomic analysis. Table 1. E. histolytica proteins used in this study.
  • the Wittrup library of human nonimmune scFv antibodies displayed on the surface of yeast was used to isolate scFv that bind to E. histolytica proteins. Following magnetic and FACS selections, sorted clones were tested for binding to cognate antigen as well as for specificity. To determine specificity, antigen-binding clones were tested for non-binding to a minimum of four additional E. histolytica-dQrb/Qd non-cognate antigens.
  • Jacob-All bound to both biotinylated and unlabeled Jacob antigen.
  • the affinity was determined to be 43 nM and this clone was selected for further lyophilization studies.
  • the 142 fragment generated a panel of yeast scFv that exhibited good binding. However, all of these scFv exhibited non-specific binding to at least one of the four non-cognate control proteins employed for the specificity analysis. No clones were isolated that bound specifically to 142.
  • yeast-scFv clones were isolated that bound specifically to 3 out of 4 protein fragments examined.
  • the following 4 yeast-scFv clones that bound specifically to putative E. histolytica cyst proteins were chosen for assay development: clones 350-E2 and 350-12 which bound the 350 antigen; clone 780-23 which bound the biotinylated 780 antigen, and clone Jacob-All which bound the Jacob antigen.
  • yeast cells were then lyophilized as described below in the EXAMPLES section.
  • Yeast that were lyophilized and rehydrated in assay wash buffer appeared morphologically similar to fresh, pre-lyophilized yeast, as determined microscopically.
  • 10 mL of fresh induced or lyophilized and rehydrated yeast-scFv clone 350-E2 were analyzed by light microscopy at 40x magnification.
  • Both pre-lyophilized yeast and reconstituted yeast appeared rounded and uniform with approximately half of the yeast in the process of budding (not shown).
  • Lyophilized yeast-scFv probes were used in three antigen detection assay formats. In one format, biotinylated antigens were captured by yeast-scFv and bound antigen was then detected by staining with streptavidin conjugated to phycoerythrin (SA-PE) followed by flow cytometric analysis (results illustrated in FIGURE 1A). In a second, more broadly useful format, unlabeled antigens were incubated with yeast-scFv and their capture was detected by incubating the complexes with rabbit polyclonal antiserum raised against the antigen. FIGURE IB shows the results of rehydrated yeast- 350-E2 binding to unlabeled 350 antigen.
  • SA-PE phycoerythrin
  • FIGURE IB shows the results of rehydrated yeast- 350-E2 binding to unlabeled 350 antigen.
  • the antigen-rabbit polyclonal antibody complex was further detected using a phycoerythrin-conjugated goat-anti-rabbit MAb (GaR-PE) and analyzed by flow cytometry.
  • the rabbit polyclonal antiserum was not affinity purified and therefore was unlikely to be fully specific to the cognate antigens. However, when such antibodies were used in sandwich assays in combination with monoclonal yeast-scFv probes, the combined assays were expected to be specific.
  • a sandwich assay incorporating yeast-scFv capture probes, polyclonal rabbit antibody signal probes and GaR-FITC detection probes were combined with an immunofluorescence (IF A) microscopy readout rather than flow cytometry (results illustrated in FIGURE 3).
  • IF A immunofluorescence
  • binding of antigen was quantified as the percent of PE-positive yeast relative to the no-antigen control. In most such assays, positive binding resulted in PE-fluorescence of approximately 45-65% of yeast cells.
  • yeast-scFv bioprobes had little effect on binding of the yeast-scFv bioprobes to antigens.
  • freshly grown yeast-scFv 350-E2 exhibited approximately 53% binding to both unlabeled (FIGURE IB) and biotinylated 350 antigen (FIGURE 1A) prior to lyophilization, and approximately 64% binding after lyophilization and reconstitution.
  • the same probe exhibited only ⁇ 6% binding to three non-cognate antigens (142, Jacob, and 780). This specificity did not change with lyophilization and rehydration, although slightly greater background binding to biotinylated noncognate antigens was observed in lyophilized yeast.
  • yeast-scFv clones i.e., 350-12, 350-10, Jacob-cl.12, Jacob-cl.5, Jacob-cl.15, 780-23, 780-18, and 780-17
  • 100 ⁇ ⁇ of either fresh or lyophilized/rehydrated yeast were stained first for c-myc-FITC expression followed by binding to cognate antigen and to a non-cognate control (100 nM antigen concentration). Binding to antigen was indicated by an increase in PE fluorescence.
  • Clones 350-10 and 780-18 are myc-negative due to premature stop codons following the scFv gene. However, these clones appeared to bind antigen before and after lyophilization. Thus, all examined clones bound their cognate antigen following lyophilization (not shown). Therefore, antigen-specific binding after lyophilization is demonstrated to be a consistent property of yeast-scFv bioprobe reagents.
  • the lyophilized yeast While appearing healthy microscopically and retaining scFv display/expression and antigen binding, the lyophilized yeast did not retain viability under the lyophilization conditions used. Attempts to culture rehydrated cells demonstrated complete loss of viability. This demonstrates, therefore, that the bioprobes of the present invention are not required to maintain viability upon preservation and/or reconstitution, but rather only require that the preservation process (e.g., lyophilization) leave the bioprobes intact with the surface display of the antigen-binding compounds.
  • the 350-E2 probe were tested against 10 concentrations of 350 antigen ranging from 20 nM to 0.04 nM in twofold serial dilutions, each in a volume of 2.5 mL. Bound 350 antigen was detected by incubation with rabbit anti-350 antiserum followed by GaR-PE and analyzed by flow cytometry. As shown in FIGURE 2, the LLD was approximately 310 picomolar, comparable to an ELISA assay using a typical monoclonal antibody. The LLD was determined as the concentration of antigen resulting in binding was two standard deviations above the "no antigen" negative control.
  • the flow cytometry-based assays are sensitive and specific; however, flow cytometry capabilities are not available to all potential users of the bioprobes (e.g., yeast-scFv bioprobes) of the present invention. Therefore, an alternative immunofluorescence microscopy assay (IFA) was developed using the lyophilized yeast-scFv bioprobes. To evaluate the IFA, the reconstituted yeast-scFv (350-E2 in FIGURE 3) were incubated with antigen in a concentration series ranging from 500 nM to 0.69 nM in threefold dilutions.
  • IFA immunofluorescence microscopy assay
  • Antigen binding was detected by staining with rabbit anti-350 antiserum followed by GaR-FITC, and quantified by fluorescence microscopy and computer-assisted image analysis as described in the EXAMPLES section below.
  • FITC fluorescence in the presence of the cognate 350 antigen was clearly visible relative to a non-cognate control antigen (antigen 142).
  • antigen 142 under increased magnification, as illustrated in FIGURE 3 A, the majority of the fluorescent staining appeared localized to the perimeter of the yeast-scFv particles, consistent with staining of the cell wall associated scFv.
  • the LLD of the IFA format was 6.17 nM (not shown).
  • lyophilized yeast-scFv The stability of lyophilized yeast-scFv over time was assessed by using clone 780-23, which is specific for 780-biotin antigen (FIGURE 5). For each time point, an aliquot of lyophilized 780-23 yeast was rehydrated, stained for scFv expression via the anti-c-myc tag, and then split into smaller aliquots. One aliquot was incubated with 100 nM 780-biotin (the cognate antigen) and other aliquots were incubated with 100 nM of three non-cognate antigens (Jacob-biotin, 142-biotin, and 350-biotin).
  • Jacob-biotin was used throughout the experiment, while the other non-cognate antigens were used only at later time points. After washing, the bound antigen was detected by the addition of SA-PE. An aliquot of unstained yeast was also analyzed as a negative control. As seen in FIGURES 1 and 2, antigen binding was quantified using flow cytometry to measure the percentage of yeast cells that expressed scFv (FITC on the x-axis) and bound to biotinylated antigen (PE on the y-axis). Binding activity was stable for at least 30 days, with decay in the PE fluorescence starting around day 35. Binding to non-cognate antigens was low throughout the experiment (FIGURE 5).
  • Affinity reagents are critical limiting factors in biomedical research and diagnostics.
  • the goal of the present efforts is to design faster, cheaper, and more versatile methods for generating new affinity reagents.
  • Yeast display libraries of human scFv have been in use for more than 10 years and are well established for rapid in vitro antibody isolation.
  • the use of scFv culled from these libraries has been limited by the slow and inefficient conversion of yeast-displayed scFv to soluble, secreted antibodies that can be incorporated into diagnostic tests.
  • yeast display and related methods have not supplanted traditional methods for generating monoclonal antibodies.
  • yeast-scFv generation and application was pursued.
  • the resulting end-use detection reagents can be generated in two to three weeks, much faster than MAb generation.
  • the bioprobe reagents can be generated efficiently in a cost-effective manner in large batches and be stored at room temperature for long periods before use.
  • the selected yeast-scFv clones that bound the biotinylated form of the protein did not bind to the biotin entity itself, as indicated by the fact that they did not bind to biotinylated non-cognate control antigens. Therefore, one explanation is that biotinylation may alter protein folding, exposing new epitopes not seen in the native protein.
  • One clone, Jacob-All bound both unlabeled and Jacob-biotin protein, however, it bound much better to Jacob-biotin.
  • Only two unique clones were isolated that bound 350 antigen. This may be because the 350 protein fragment used for selections was small ( ⁇ 18 kDa) and, therefore, may have presented a small number of epitopes.
  • One of these clones, 350-E2 bound labeled and unlabeled 350 antigen equally well and was isolated more than 20 times from multiple independent selections. This clone was used for most of the subsequent work.
  • a major goal of the study was to determine whether whole (i.e., intact) yeast displaying scFv could be preserved by lyophilization.
  • Yeast clones were induced to express scFv on their surfaces and then lyophilized in single use aliquots. Microscopically, lyophilized/reconstituted yeast were indistinguishable from freshly induced yeast. By flow cytometry, the rehydrated yeast exhibited much lower side scatter fluorescence, suggesting that they lacked the complexity/granularity of fresh yeast.
  • the lyophilized yeast did not form colonies when plated on SDCAA medium (synthetic dextrose medium with casamino acids deficient in histidine, uracil, and tryptophan).
  • the loss of viability and shift in side scatter fluorescence may be a result of the simple lyophilization protocol, which did not use cryoprotectants. However, the goal was not to maintain cell viability, but rather to maintain the specific antigen-binding activities of the surface-displayed scFv after lyophilization and subsequent reconstitution.
  • the lyophilized yeast were stored at room temperature, reconstituted in simple buffers (typically PBS or PBS+5% BSA), and were immediately usable following rehydration. Although stabilizers such as lyophilization buffers, nitrogen gas, oxygen absorbers, and desiccants were not used, all three yeast-scFv bioprobe clones examined maintained stable binding for at least 30 days. Longer shelf lives may be possible when yeast-scFv are stored with cooling or desiccants.
  • Lyophilization of yeast-scFv facilitates storage and shipment. Moreover, it abrogates the need for overnight growth of yeast in SDCAA medium, followed by overnight induction of scFv expression in SG/RCAA media, as well as the need to perform quality control (QC) analysis of each induction. With lyophilized yeast cultures, the QC is performed just once immediately prior to lyophilization. A typical flow cytometry assay, such as illustrated in FIGURE 1, requires approximately le7 yeast. With lyophilization, liter-scale batches of induced yeast (at a concentration of 2-4e7 yeast per mL) can be stored in single-use aliquots of le7 yeast. This means that a single 1 -liter culture of induced yeast-scFv can yield enough material for up to 4000 tests at a cost of a few pennies per test.
  • polyclonal detection antibodies are inexpensive and easy reagents to prepare.
  • whole-cell yeast-scFv affinity reagents can be rapidly selected and prepared in lyophilized form. With its fast turnaround time (3 weeks from expressed antigen to lyophilized probe) and low cost, the process has utility to produce affinity reagent compositions that can routinely overcome a significant bottleneck in diagnostics and research.
  • the polyclonal rabbit anti-350 and anti-780 antisera were both generated by Cocalico Biologicals, Inc. (Reamstown, PA).
  • Proteins 780, 350, 142, and Jacob were biotinylated using either the Pierce EZ-Link Peg-Biotin or the Sulfo-NHS-LC-Biotin kit (Thermo Scientific, Rockford, IL) per manufacturer's instructions. The degree of biotinylation was quantified using the Pierce Biotin Quantitation (HABA) Assay (Thermo Scientific, Rockford, IL).
  • E. histolytica Jacob protein compared to E. dispar and E. moshkovskii proteins
  • codon optimized GeneArt, Invitrogen
  • topo-cloned into the pET SUMO vector The correct orientation of insert in pET SUMO vector was verified by DNA sequencing.
  • chromodomain proteins For the chromodomain proteins (Genbank nos.: EHI 000780, EHI l 15350, and EHI_142000), DNA segments corresponding to the selected region of proteins were PCR amplified from the E. histolytica genomic DNA, digested with Ndel and BamHl restriction enzymes, gel-purified, and ligated to pETl la vector using the T4 DNA ligase. Top 10 cells were then transformed using the pETl la vector containing the insert. Both pET SUMO vector and pETl la vectors contain sequences for 6 histidine residues N-terminal to the gene of interest, allowing each protein to be purified using the Ni-NTA column according to the manufacturer's instructions (Qiagen). The SUMO fusion protein was cleaved from the is/Jacob with the treatment of SUMO protease (LifeSensors, Malvern, PA).
  • Yeast were routinely grown in SDCAA broth. To induce expression of scFv on the yeast surface, yeast were grown in selective synthetic galactose/raffinose plus casamino acids deficient in histidine, uracil, and tryptophan (SG/RCAA) broth. For round 1 (Rl) and round 2 (R2) of selection, 10 10 yeast were incubated in 10 mL yeast wash buffer (YWB; PBS 0.5% BSA) containing 100 nM of each of the four biotinylated proteins separately. Yeast that bound protein were then labeled by incubation with 200 ⁇ of either streptavidin-magnetic particles (Rl) or anti-biotin magnetic particles (R2).
  • the eluted yeast (R2 output) were incubated with 1 ⁇ g mL "1 SA-PE. Yeast were then sorted by FACS for the top 10% of PE-positive cells and expanded into 5 mL of SDCAA broth (sorted yeast comprised the R3 output). For round 4 (R4) of the selection, the R3a outputs were incubated with anti-c-myc MAb and goat-antimouse-fluorescein isothiocyanate (GaM-FITC) to confirm expression of scFv before again being incubated with 100 nM of their specific biotinylated antigen followed by SA-PE.
  • GaM-FITC goat-antimouse-fluorescein isothiocyanate
  • Yeast were then sorted by FACS for FITC-positive and the top 10% of PE-positive signal.
  • Antigen-binding yeast were grown on synthetic dextrose casamino acids minus His, Ura, Trp plate (-HUT media) for single clone analysis.
  • 24 ⁇ 18 clones were picked and grown in 96 deep well plates in 1 mL of SDCAA broth.
  • each clone was then tested by flow cytometry for binding to cognate antigen and for non-binding to all non-cognate antigens or the secondary reagents (SA-PE, FITC) themselves.
  • Antigen-specific clones were then amplified by PCR, and the PCR amplicon was subjected to BstNl fingerprint analysis as described previously (Gray, S.A., et al, "Synergistic Capture of Clostridium botulinum Type A Neurotoxin by scFv Antibodies to Novel Epitopes," Biotechnol Bioeng, 201 1; Gray, S.A., et al, "Flow Cytometry-Based Methods for Assessing Soluble scFv Activities and Detecting Antigens in Solution,” Biotechnol Bioeng 705:973-981, 2010).
  • the 850-1000 nucleotide PCR amplicons are digested with the restriction endonuclease Bsf l, usually resulting in 3-8 smaller fragments.
  • the resulting fragment pattern, or fingerprint, after resolving the fragments by DNA gel electrophoresis was used to determine uniqueness. All apparently unique clones were then DNA sequenced to confirm uniqueness and confirmed clones were used in the study.
  • yeast-displaying scFv were incubated with twofold serial dilutions of biotinylated antigens spanning 3.125-250 nM in concentration and antigen binding was determined by further staining with SA-PE. Samples were analyzed by flow cytometry, results graphed as a function of antigen-biotin concentration versus mean PE fluorescence.
  • This assay was used to measure the affinities of clones 780-23, Jacob-All, 350-12, and 350-E2 (binding to 350-biotin).
  • the affinity of clone 350-E2 to unlabeled 350 was measured by using a modification of this assay, in which binding was detected by staining the yeast-antigen complexes with a rabbit anti-350 polyclonal serum and then further stained with goat-anti rabbit PE.
  • the affinity of clone Jacob-All to unlabeled Jacob protein was not tested.
  • the beaker was immediately capped, fit to the lyophilizer, and vacuum applied.
  • Yeast were lyophilized overnight using a Millrock Technology Model BT48A lyophilizer (Kingston, NY). Following lyophilization, tubes were tightly capped and stored at room temperature without desiccants or stabilizers.
  • yeast One aliquot of fresh, non-lyophilized 350-E2 yeast and one aliquot of lyophilized, rehydrated yeast ( ⁇ l xl0 7 yeast/aliquot) were incubated with anti-c-myc MAb followed by goat-anti-mouse FITC detection MAb to confirm expression of scFv. Following c-myc staining, the yeast were split into two sets of five equal aliquots. One set was incubated with 100 nM of biotinylated cognate antigen and three biotinylated non-cognate antigens (plus the no-antigen control) for 1 hr at RT.
  • Binding of biotinylated antigens was detected by addition of 100 ⁇ , of a 1/800 dilution of SA-PE for 30 minutes. The second set of aliquots received 100 nM of unlabeled 350, 142, Jacob, and 780 (plus the no-antigen control). To detect binding of unlabeled antigens, the yeast were incubated with a 1/1000 dilution of rabbit anti-350 antiserum for 45 min at RT followed by a 1/800 dilution of goat-anti-rabbit-PE for 45 min at RT.
  • Yeast were then analyzed by flow cytometry for scFv expression (x-axis; FITC fluorescence) and antigen binding (y-axis; PE fluorescence).
  • the assay was performed three times, and each assay utilized an independent induction and lyophilization of yeast 350-E2.
  • the percent PE fluorescent yeast were determined by gating the percent PE-positive relative to the "no antigen" controls. All other yeast clones isolated in this study were analyzed for specificity in a similar fashion.
  • lyophilized 350-E2 yeast clone was reconstituted in 1 mL YWB and split into 8 equal aliquots. Each aliquot received 100 of 7 concentrations of cognate 350 or non-cognate 142 ranging from 500 nM to 0.69 nM in threefold serial dilutions (plus the 0 nM control). Bound antigens were detected by incubating with a 1/2500 dilution of rabbit anti-350 antiserum followed by 1/800 dilution of goat-anti-rabbit-FITC (GaR-FITC) detection MAb for 1 hr.
  • GaR-FITC goat-anti-rabbit-FITC
  • yeast pellets were resuspended in 100 ⁇ , and 10 of yeast were spotted onto microscope slides and a coverslip applied.
  • the yeast were imaged at 40x magnification using a Nikon TE2000U inverted microscope (Nikon Corporation, Tokyo, Japan) outfitted with phase contrast and DIC optics for visible imaging, a FITC filter, a high-speed Cool Snap CCD camera, and a motorized stage for automated scanning. Image capture and analysis was performed using Metamorph software (Research Precision Instruments, Natick, MA).
  • a second experiment was similarly performed to enumerate the approximate number of FITC-positive yeast relative to a concentration of cognate antigen.
  • yeast were incubated with 1 1 concentrations of unlabeled 350 antigen ranging from 160 nM down to 0.16 nM in twofold serial dilutions.
  • a minimum of 3 independent fields were captured in visible mode followed immediately by the same three fields in FITC fluorescence mode.
  • Total and FITC-fluorescent yeast were counted in each field using the Image J Software (Rasband, W.S., ImageJ, U.S. National Institutes of Health, Bethesda, Maryland, USA, imagej.nih.gov/ij/, 1997-2011).
  • Visible fields were background-subtracted with a 50-pixel rolling ball radius while sliding paraboloid was enabled and automated smoothing disabled. Automatic thresholding was performed in grayscale with the default settings. Particles (cells) were analyzed from 64- ⁇ without circularity compensation, with edge exclusion and hole inclusion. Fluorescent (FITC) fields were background-subtracted in the same fashion. Each FITC image then underwent a binary conversion allowing the watershed filter to be applied. After automatic triangle thresholding in grayscale using a dark background, the fluorescent particles were enumerated from 64- ⁇ without circularity compensation. In each field, percent fluorescence was calculated from the ratio of the number of fluorescent yeast (FITC) to the total number of yeast in the visible spectrum. The percentages were averaged and standard deviations calculated from at least three fields at a given antigen concentration.
  • FITC fluorescent yeast
  • Lyophilization time course assay In this Example, a method and reagents for confirming the stability of lyophilized yeast bioprobe reagents are described.
  • yeast-scFv To assess the stability of yeast-scFv following lyophilization, a fresh culture of yeast clone 780-23 was induced for expression of scFv and lyophilized in individual aliquots containing ⁇ l x l0 7 yeast. For the first two weeks, time points were taken twice weekly, and from then on time points were taken approximately once per week until little binding to cognate antigen was observed.
  • yeast For each time point, one aliquot of lyophilized yeast was reconstituted in 1 mL YWB, stained for c-myc expression as described previously, and then split into 5 equal aliquots. The aliquots received 100 ⁇ ⁇ of 100 nM of one of either cognate 780-biotin or non-cognate Jacob-biotin antigen (plus a no-antigen control). Following 45 min of antigen binding, yeast were washed 2x and bound antigen detected by incubation with a 1/800 dilution of SA-PE. Yeast were washed 3x and analyzed for FITC (x-axis) and PE (y-axis) fluorescence by flow cytometry.
  • a gate was set to measure the total percent of PE-positive yeast relative to the "no antigen" control. The percent of antigen binding (percent PE-positive) was then plotted versus the day post lyophilization. The cognate antigen throughout this assay was 780-biotin, and the non-cognate antigen was Jacob-biotin. Starting at day 30, two other non-cognate antigens, 350-biotin and 142-biotin, were included to better assess specificity. The assay was terminated on day 86 when binding to cognate antigen had dropped below 15%.
  • the stability of the yeast bioprobe clone 350-12 was similarly assessed. Briefly, three individual colonies of clone 350-12 were lyophilized separately on different days. Every 3 to 5 days, one aliquot of each was tested for binding to cognate antigen (100 nM 350-biotin) and to a non-cognate control antigen (100 nM 780-biotin) as described above for yeast bioprobe clone 780-23. Because of the staggered lyophilization dates, data were grouped into groups of 2 to 3 days, each point representing the average and standard deviation for the day groupings.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention concerne des compositions de sondes biologiques permettant de se fixer sélectivement à un antigène présentant un intérêt dans un échantillon. L'invention concerne également des méthodes et des kits associés. Les compositions de sondes biologiques comprennent des particules lyophilisées présentant des molécules de fixation antigénique à la surface externe, qui maintiennent leur intégrité structurelle et fonctionnelle après lyophilisation et reconstitution.
PCT/US2012/038684 2011-05-19 2012-05-18 Compositions de sondes biologiques et leurs méthodes d'utilisation Ceased WO2012159075A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161487903P 2011-05-19 2011-05-19
US61/487,903 2011-05-19

Publications (1)

Publication Number Publication Date
WO2012159075A1 true WO2012159075A1 (fr) 2012-11-22

Family

ID=47177368

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/038684 Ceased WO2012159075A1 (fr) 2011-05-19 2012-05-18 Compositions de sondes biologiques et leurs méthodes d'utilisation

Country Status (1)

Country Link
WO (1) WO2012159075A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014093357A1 (fr) * 2012-12-10 2014-06-19 The University Of Queensland Compositions de biofragments sans cellules, et systèmes, dispositifs et procédés correspondants
US11604026B2 (en) 2019-03-14 2023-03-14 Terumo Bct Biotechnologies, Llc Lyophilization loading tray assembly and system
US11634257B2 (en) 2017-10-09 2023-04-25 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003031591A2 (fr) * 2001-10-10 2003-04-17 Superarray Bioscience Corporation Detection de cibles a l'aide de marqueurs uniques d'identification de nucleotides
WO2007047796A2 (fr) * 2005-10-17 2007-04-26 Institute For Systems Biology Glycoproteines derivees de tissus et du serum et leurs methodes d'utilisation
WO2009058564A2 (fr) * 2007-11-01 2009-05-07 Maxygen, Inc. Polypeptide immunosuppresseur et acides nucléiques
US20100303827A1 (en) * 2007-11-28 2010-12-02 One Medimmune Way Protein Formulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003031591A2 (fr) * 2001-10-10 2003-04-17 Superarray Bioscience Corporation Detection de cibles a l'aide de marqueurs uniques d'identification de nucleotides
WO2007047796A2 (fr) * 2005-10-17 2007-04-26 Institute For Systems Biology Glycoproteines derivees de tissus et du serum et leurs methodes d'utilisation
WO2009058564A2 (fr) * 2007-11-01 2009-05-07 Maxygen, Inc. Polypeptide immunosuppresseur et acides nucléiques
US20100303827A1 (en) * 2007-11-28 2010-12-02 One Medimmune Way Protein Formulation

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014093357A1 (fr) * 2012-12-10 2014-06-19 The University Of Queensland Compositions de biofragments sans cellules, et systèmes, dispositifs et procédés correspondants
AU2013359469B2 (en) * 2012-12-10 2019-05-16 Seattle Biomedical Research Institute Cell-free biofragment compositions and related systems, devices, and methods
EP2929351B1 (fr) * 2012-12-10 2019-10-09 The University of Queensland Compositions de biofragments sans cellules, et systèmes, dispositifs et procédés correspondants
US11105802B2 (en) 2012-12-10 2021-08-31 Seattle Children's Hospital Cell-free biofragment compositions and related systems, devices, and methods
US11634257B2 (en) 2017-10-09 2023-04-25 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
US11604026B2 (en) 2019-03-14 2023-03-14 Terumo Bct Biotechnologies, Llc Lyophilization loading tray assembly and system
US11609043B2 (en) 2019-03-14 2023-03-21 Terumo Bct Biotechnologies, Llc Lyophilization container fill fixture, system and method of use
US11609042B2 (en) 2019-03-14 2023-03-21 Terumo Bct Biotechnologies, Llc Multi-part lyophilization container and method of use
US11740019B2 (en) 2019-03-14 2023-08-29 Terumo Bct Biotechnologies, Llc Lyophilization loading tray assembly and system
US11747082B2 (en) 2019-03-14 2023-09-05 Terumo Bct Biotechnologies, Llc Multi-part lyophilization container and method of use
US11815311B2 (en) 2019-03-14 2023-11-14 Terumo Bct Biotechnologies, Llc Lyophilization container fill fixture, system and method of use
US11994343B2 (en) 2019-03-14 2024-05-28 Terumo Bct Biotechnologies, Llc Multi-part lyophilization container and method of use

Similar Documents

Publication Publication Date Title
Van Deventer et al. Yeast surface display for antibody isolation: library construction, library screening, and affinity maturation
CN104034882B (zh) 用于测定样本中的待测定成分的方法和试剂盒
AU2013222411B2 (en) Methods and systems for detection of microorganisms
Skottrup et al. Rapid determination of Phytophthora infestans sporangia using a surface plasmon resonance immunosensor
CN102399753B (zh) 一种小麦矮腥黑粉菌的特异性单克隆抗体及免疫荧光检测方法
JPWO2011081075A1 (ja) 黄色ブドウ球菌抗原の抽出方法、黄色ブドウ球菌抗原の抽出用試薬および黄色ブドウ球菌の判定方法
Stewart et al. Development of a novel phage‐mediated immunoassay for the rapid detection of viable Mycobacterium avium subsp. paratuberculosis
Xu et al. Rapid detection of Campylobacter jejuni using fluorescent microspheres as label for immunochromatographic strip test
Spadafora et al. Species-specific immunodetection of an Entamoeba histolytica cyst wall protein
Mazzega et al. In vitro isolation of nanobodies for selective Alexandrium minutum recognition: A model for convenient development of dedicated immuno-reagents to study and diagnostic toxic unicellular algae
Gray et al. Toward low-cost affinity reagents: lyophilized yeast-scFv probes specific for pathogen antigens
JPH03277972A (ja) リステリア菌の検出方法
KR102686392B1 (ko) 항 범종 특이적 말라리아 원충 젖산 탈수소효소의 항체
EP2405268A1 (fr) Procédé de détection d'une substance dans un échantillon biologique
CN111100199A (zh) 一种荧光素标记的蛋白四聚体及其制备方法与应用
WO2012159075A1 (fr) Compositions de sondes biologiques et leurs méthodes d'utilisation
Rahbarnia et al. Comparative evaluation of nested polymerase chain reaction for rapid diagnosis of human brucellosis
US20220120745A1 (en) Cell-free biofragment compositions and related systems, devices, and methods
Love et al. Real time detection of anthrax spores using highly specific anti-EA1 recombinant antibodies produced by competitive panning
JP2010187665A (ja) オキサ型β−ラクタマーゼ産生菌の検出方法、同定方法及びキット
Liu et al. Selection and characterization of single-chain recombinant antibodies against spring viraemia of carp virus from mouse phage display library
US20150079597A1 (en) Method for capturing and concentrating a microorganism in a biological sample
Mihklepp et al. Immunodetection of Streptococcus uberis pathogen in raw milk
Mihklepp et al. Design and production of antibodies for the detection of Streptococcus uberis
US8591899B2 (en) Diagnosis of Bacillus anthracis infection based on detection of bacterial secreted biomarkers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12785232

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12785232

Country of ref document: EP

Kind code of ref document: A1